OncoMatch/Clinical Trials/NCT06706401
Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma
Is NCT06706401 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Vesanoid and Cisplatin for oropharynx cancer.
Treatment: Vesanoid · Cisplatin · Cetuximab — The aim of this study is to investigate the effect of ATRA (Vesanoid) and the effect of tailored radiotherapy in patients with squamous cell carcinoma of the oropharynx, larynx or hypopharynx.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Allowed: CDKN2A p16 overexpression
the oropharynx p16+
Allowed: CDKN2A p16 negative
the oropharynx p16-
Disease stage
Required: Stage T1/N2A-N2B, T2/N0-N2B, T3/N0-N2B, T1/N1 (MULTIPLE NODES), T2/N0-N1, T2/N1, T3/N0-N1, T3/N1 (UICC 8th Ed.)
Excluded: Stage T1-N0 (P16-), T1-N1 (P16-), T1-N0 (P16+), T4 (P16- AND P16+), T0-N1 TO T0-N3 (P16- OR P16+)
the oropharynx p16-, larynx or hypopharynx : T1/N2a-N2b, T2/N0-N2b, T3/N0-N2b (UICC 8th Ed.), or the oropharynx p16+ : T1/N1 (multiple nodes), T2-T3/N0-N1 (UICC 8th Ed.)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
any previous anti-cancer therapy for HNSCC (all prior treatment are forbidden: chemotherapy, radiotherapy, targeted therapy, immunotherapy or any other therapy approved or experimental)
Cannot have received: radiotherapy
any previous anti-cancer therapy for HNSCC (all prior treatment are forbidden: chemotherapy, radiotherapy, targeted therapy, immunotherapy or any other therapy approved or experimental)
Cannot have received: targeted therapy
any previous anti-cancer therapy for HNSCC (all prior treatment are forbidden: chemotherapy, radiotherapy, targeted therapy, immunotherapy or any other therapy approved or experimental)
Cannot have received: immunotherapy
any previous anti-cancer therapy for HNSCC (all prior treatment are forbidden: chemotherapy, radiotherapy, targeted therapy, immunotherapy or any other therapy approved or experimental)
Lab requirements
Blood counts
Neutrophils count > 1.5 × 10^9 /L; Platelets count > 75 × 10^9 /L; WBC≥ 3.0 × 10^9 /L
Kidney function
Serum creatinine < 1.5 ×ULN.
Liver function
Total Bilirubin < 1.5 × ULN (except for Gilbert's syndrome which will allow bilirubin ≤ 3 ULN). Alanine aminotransferase (ALT) ≤ 2.5 × ULN. Aspartate aminotransferase (AST) ≤ 2.5 × ULN. Albumin >3.0g/dL
Cardiac function
QTcF ≤450ms for men and 470ms for women, from 3 electrocardiograms on screening ECG, within 7 days prior randomisation.
Adequate hematologic and end-organ function, defined by the following laboratory test results obtained within 7 days prior to randomisation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify